Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

Model selection and multimodel inference: a practical information-theoretic approach.

Guthery, F. S., Burnham, K. P., & Anderson, D. R. (2003) · The Journal of Wildlife Management · doi:10.2307/3802723 · Cited by 41,495 · see citing works

Numerical recipes in C: the art of scientific computing

(1993) · Choice Reviews Online · doi:10.5860/choice.30-5638 · Cited by 17,933 · see citing works

Nonlinear Regression Analysis and Its Applications

Bates, D. M., & Watts, D. G. (1988) · Wiley series in probability and statistics · doi:10.1002/9780470316757 · Cited by 4,017 · see citing works

Epidermal growth factor receptor mutations in lung cancer

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · see citing works

The resurgence of covalent drugs

Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · see citing works

Program DYNAFIT for the Analysis of Enzyme Kinetic Data: Application to HIV Proteinase

Kuzmič, P. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0238 · Cited by 1,499 · see citing works

Drug-target residence time and its implications for lead optimization

Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464 · see citing works

Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.

Copeland, R. A. (2005) · PubMed · Cited by 1,045 · see citing works

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991 · see citing works

Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors

Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 815 · see citing works

Evaluation of Enzyme Inhibitors in Drug Discovery

Copeland, R. A. (2013) · Wiley eBooks · doi:10.1002/9781118540398 · Cited by 689 · see citing works

Global Kinetic Explorer: A new computer program for dynamic simulation and fitting of kinetic data

Johnson, K. A., Simpson, Z. B., & Blom, T. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.12.024 · Cited by 596 · see citing works

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Burstein, H. J., Sun, Y. P., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A. H., Ranade, A. A., Jiao, S., Schwartz, G. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8707 · Cited by 522 · see citing works

Orchestrating Redox Signaling Networks through Regulatory Cysteine Switches

Paulsen, C. E., & Carroll, K. S. (2009) · ACS Chemical Biology · doi:10.1021/cb900258z · Cited by 478 · see citing works

Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity

Paulsen, C. E., Truong, T. H., García, F., Homann, A., Gupta, V., Leonard, S. E., & Carroll, K. S. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.736 · Cited by 473 · see citing works

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

Yang, J. C., Shih, J., Su, W., Hsia, T., Tsai, C., Ou, S. I., Yu, C., Chang, G., Ho, C., Sequist, L. V. D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70086-4 · Cited by 410 · see citing works

[10] Mechanism-based enzyme inactivators

Silverman, R. B. (1995) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(95)49038-8 · Cited by 389 · see citing works

Discovering mechanisms of signaling-mediated cysteine oxidation

Poole, L. B., & Nelson, K. J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.01.021 · Cited by 389 · see citing works

[2] Global analysis of biochemical and biophysical data

Beechem, J. (1992) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(92)10004-w · Cited by 379 · see citing works

Endosomes: A legitimate platform for the signaling train

Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S., & Bunnett, N. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906541106 · Cited by 373 · see citing works

FitSpace Explorer: An algorithm to evaluate multidimensional parameter space in fitting kinetic data

Johnson, K. A., Simpson, Z. B., & Blom, T. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.12.025 · Cited by 344 · see citing works

6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity

Tsou, H., Mamuya, N. N., Johnson, B. D., Reich, M. F., Gruber, B. C., Ye, F., Nilakantan, R., Shen, R., Discafani, C. M., DeBlanc, R., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0005555 · Cited by 269 · see citing works

Differential Evolution

Price, K. V., Storn, R., & Lampinen, J. (2005) · Springer eBooks · doi:10.1007/3-540-31306-0 · Cited by 259 · see citing works

DynaFit—A Software Package for Enzymology

Kuzmič, P. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)67010-5 · Cited by 256 · see citing works

A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding

Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., & Okazaki, O. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027797 · Cited by 252 · see citing works

Chapter 23 Fitting Enzyme Kinetic Data with KinTek Global Kinetic Explorer

Johnson, K. A. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)67023-3 · Cited by 240 · see citing works

Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase

Williams, J. W., Morrison, J. F., & Duggleby, R. G. (1979) · Biochemistry · doi:10.1021/bi00579a021 · Cited by 228 · see citing works

Redox Regulation of Epidermal Growth Factor Receptor Signaling through Cysteine Oxidation

Truong, T. H., & Carroll, K. S. (2012) · Biochemistry · doi:10.1021/bi301441e · Cited by 198 · see citing works

Models of S/π interactions in protein structures: Comparison of the H2S–benzene complex with PDB data

McDonald, A. R., Senenko, A., & Sherrill, C. D. (2007) · Protein Science · doi:10.1110/ps.073002307 · Cited by 196 · see citing works

Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors

Leproult, É., Barluenga, S., Moras, D., Wurtz, J., & Winssinger, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101396q · Cited by 196 · see citing works

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Jänne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., Guo, F., Wong, S., Liang, J., Letrent, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1220 · Cited by 181 · see citing works

The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

Wissner, A., & Mansour, T. S. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200800009 · Cited by 179 · see citing works

Protein kinase biochemistry and drug discovery

Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 157 · see citing works

Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer

Janne, P. A., von Pawel, J., Cohen, R. B., Crinò, L., Butts, C. A., Olson, S. S., Eiseman, I. A., Chiappori, A., Yeap, B. Y., Lenehan, P. F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1336 · Cited by 120 · see citing works

Recognition-Domain Focused Chemosensors: Versatile and Efficient Reporters of Protein Kinase Activity

Luković, E., Gonzalez‐Vera, J. A., & Imperiali, B. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8046188 · Cited by 118 · see citing works

[6] Kinetics of slow and tight-binding inhibitors

Szedlacsek, S. E., & Duggleby, R. G. (1995) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(95)49034-5 · Cited by 117 · see citing works

Functionally Important Aromatic–Aromatic and Sulfur−π Interactions in the D2 Dopamine Receptor

Daeffler, K. N.-M., Lester, H. A., & Dougherty, D. A. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304560x · Cited by 115 · see citing works

Trafficking of receptor tyrosine kinases to the nucleus

Carpenter, G. F., & Liao, H. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.09.027 · Cited by 113 · see citing works

Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations

Avizienyte, E., Ward, R. A., & Garner, A. P. (2008) · Biochemical Journal · doi:10.1042/bj20080728 · Cited by 88 · see citing works

Irreversible Protein Kinase Inhibitors

Garuti, L., Roberti, M., & Bottegoni, G. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391705 · Cited by 74 · see citing works

EGF Receptor Exposed to Oxidative Stress Acquires Abnormal Phosphorylation and Aberrant Activated Conformation That Impairs Canonical Dimerization

Filosto, S., Khan, E. M., Tognon, E., Becker, C. R., Ashfaq, M., Ravid, T., & Goldkorn, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023240 · Cited by 72 · see citing works

Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies

Yu, Z., Boggon, T. J., Kobayashi, S. S., Jin, C., Ma, P. C., Dowlati, A., Kern, J. A., Tenen, D. G., & Halmos, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1248 · Cited by 71 · see citing works

Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer

Heuckmann, J. M., Rauh, D., & Thomas, R. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1825 · Cited by 61 · see citing works

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

Rixe, O., Franco, S. X., Yardley, D. A., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0975-z · Cited by 57 · see citing works

The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer

Kwak, E. L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0087 · Cited by 44 · see citing works

Mechanistic Effects of Autophosphorylation on Receptor Tyrosine Kinase Catalysis: Enzymatic Characterization of Tie2 and Phospho-Tie2

Murray, B. W., Padrique, E., Pinko, C., et al. (2001) · Biochemistry · doi:10.1021/bi010959e · Cited by 41 · see citing works

[21] Determining confidence intervals for parameters derived from analysis of equilibrium analytical ultracentrifugation data

Brooks, I. S., Watts, D. G., Soneson, K. K., & Hensley, P. (1994) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(94)40060-1 · Cited by 31 · see citing works

Chapter 22 Enzyme Kinetics and Computational Modeling for Systems Biology

Mendes, P., Messiha, H. L., Malys, N., & Hoops, S. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)67022-1 · Cited by 31 · see citing works

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Singh, J., Evans, E. K., Hagel, M., Labinski, M., Dubrovskiy, A., Nacht, M., Petter, R. C., Prasad, A., Sheets, M. P., Martin, T. S., et al. (2012) · MedChemComm · doi:10.1039/c2md20017a · Cited by 27 · see citing works

A ZONE CLASSIFICATION SYSTEM FOR RISK ASSESSMENT OF IDIOSYNCRATIC DRUG TOXICITY USING DAILY DOSE AND COVALENT BINDING

Nakayama, S., Atsumi, R., Takakusa, H., et al. (2010) · Medical Entomology and Zoology · Cited by 14 · see citing works

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Kinase inhibitors: the road ahead

Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009 · see citing works

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583 · see citing works

Targeted Covalent Inhibitors for Drug Design

Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578 · see citing works

Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies

Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534 · see citing works

Covalent Inhibition in Drug Discovery

Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265 · see citing works

Reactive-cysteine profiling for drug discovery

Maurais, A. J., & Weerapana, E. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.010 · Cited by 167 · see citing works

Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation

Zhang, T., Hatcher, J. M., Teng, M., Gray, N. S., & Kostic, M. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.09.012 · Cited by 178 · see citing works

Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity

Lonsdale, R., Burgess, J., Colclough, N., Davies, N. L., Lenz, E. M., Orton, A. L., & Ward, R. A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00553 · Cited by 190 · see citing works

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2<i>S</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

Thorarensen, A., Dowty, M. E., Banker, M. E., Juba, B., Jussif, J., Lin, T., Vincent, F., Czerwinski, R. M., Casimiro-Garcia, A., Unwalla, R., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01694 · Cited by 176 · see citing works

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P. (2018) · Nature Structural &amp; Molecular Biology · doi:10.1038/s41594-018-0061-5 · Cited by 153 · see citing works

Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations

Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00480 · Cited by 137 · see citing works

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121 · see citing works

The Design of Covalent Allosteric Drugs

Nussinov, R., & Tsai, C.-J. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124401 · Cited by 112 · see citing works

New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design

Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108 · see citing works

Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97 · see citing works

The design and development of covalent protein-protein interaction inhibitors for cancer treatment

Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98 · see citing works

Privileged Electrophile Sensors: A Resource for Covalent Drug Development

Long, M. J. C., & Aye, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.023 · Cited by 81 · see citing works

Modeling covalent-modifier drugs.

Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90 · see citing works

Structure and Characterization of a Covalent Inhibitor of Src Kinase

Gurbani, D., Du, G., Henning, N. J., Rao, S., Bera, A. K., Zhang, T., Gray, N. S., & Westover, K. D. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00081 · Cited by 29 · see citing works

The Utilization of N-Acetylcysteine and 2-Oxothiazolidine-4-Carboxylate by Rat Hepatocytes Is Limited by Their Rate of Uptake and Conversion to Cysteine

Banks, M. F., & Stipanuk, M. H. (1994) · Journal of Nutrition · doi:10.1093/jn/124.3.378 · Cited by 39 · see citing works

Rat Liver Glutathione: Possible Role as a Reservoir of Cysteine

Tateishi, N., Higashi, T., Naruse, A., et al. (1977) · Journal of Nutrition · doi:10.1093/jn/107.1.51 · Cited by 219 · see citing works

Astrocytes Provide Cysteine to Neurons by Releasing Glutathione

Wang, X. F., & Cynader, M. S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741434.x · Cited by 281 · see citing works

Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix

Uhm, J. H., Dooley, N. P., Oh, L. Y. S., & Yong, V. W. (1998) · Glia · doi:10.1002/(sici)1098-1136(199801)22:1 · Cited by 144 · see citing works

13C-NMR spectroscopic studies of 2-mercaptoethanol-stimulated glutathione synthesis in the intact ocular lens

Willis, J., & Schleich, T. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(94)00195-k · Cited by 13 · see citing works